Perinatal endocrine testing refers to the laboratory measurement of hormones and metabolic biomarkers during pregnancy and the immediate postnatal period, supporting the diagnosis and management of gestational diabetes, thyroid dysfunction, adrenal disorders, and congenital endocrine diseases in newborns. Accredited third-party laboratories and hospital clinical laboratories perform these assays using automated immunoassay platforms and liquid chromatography–tandem mass spectrometry under ISO 15189-accredited quality management systems. This article outlines the sample types, analytes, analytical methods, clinical applications, and frequently asked questions related to perinatal endocrine testing.
Technical Overview
Perinatal endocrine testing covers the quantitative analysis of hormonal and metabolic markers from late pregnancy through the neonatal period, with many testing programs extending across the entire gestational timeline. Pregnancy induces profound physiological endocrine changes, including a marked rise in human chorionic gonadotropin (hCG), a tenfold to twentyfold increase in estradiol and progesterone of placental origin, estrogen-driven elevation of thyroxine-binding globulin (TBG), placental-lactogen-mediated insulin resistance, and increased cortisol driven by higher corticosteroid-binding globulin levels. These adaptations mean that reference intervals for endocrine analytes must be interpreted against gestational age-specific and method-specific ranges rather than general adult ranges.
Typical areas covered by perinatal endocrine testing include pregnancy viability and maintenance markers (hCG, progesterone, estradiol), maternal thyroid function, glucose metabolism and gestational diabetes mellitus (GDM) assessment, adrenal and androgen markers relevant to congenital adrenal hyperplasia (CAH), calcium and vitamin D homeostasis, and neonatal screening for congenital hypothyroidism and CAH. Laboratories performing this work generally operate under ISO 15189 (medical laboratory quality and competence) with method traceability to WHO and IFCC reference materials where available, and follow CLSI guidance for reference interval establishment and verification.
Testing Samples
Maternal Serum
Venous blood collected in serum separator tubes and centrifuged within two hours is the primary matrix for hCG, progesterone, estradiol, thyroid hormones, antibody titers, 17-hydroxyprogesterone, and vitamin D. Morning collection is preferred for cortisol and androgens to account for circadian variation, and collection timing relative to oral glucose tolerance testing must be documented for glucose interpretation.
Maternal Plasma and Whole Blood
Fluoride-oxalate or heparinized plasma is used for glucose determinations, particularly during the 75-g oral glucose tolerance test (OGTT). Whole blood in EDTA is required for glycated hemoglobin (HbA1c) and is accepted for certain hemolysis-insensitive point-of-care glucose protocols after appropriate validation.
Maternal Urine
Random midstream urine supports screening for glucosuria and ketonuria during prenatal visits, while 24-hour urine collections may be used for urinary free cortisol, urinary protein-to-creatinine assessment in preeclampsia workups, and iodine status evaluation in populations at risk of deficiency.
Neonatal Dried Blood Spots
Heel-prick capillary blood spotted onto standardized filter paper cards, collected between 48 and 72 hours of life and after adequate protein intake, is the internationally accepted matrix for newborn endocrine screening of TSH (congenital hypothyroidism) and 17-hydroxyprogesterone (CAH). Cards must be air-dried, transported at controlled humidity and temperature, and processed within defined stability windows consistent with regional newborn screening program requirements.
Cord Blood and Amniotic Fluid
Umbilical venous serum collected at delivery provides a baseline snapshot of fetal-placental hormone status and is used for neonatal thyroid follow-up or cortisol measurement in selected cases. Amniotic fluid analysis is now rarely required for endocrine purposes but may be used in second-tier assessment of fetal adrenal steroid profiles in specialized centers.
Testing Items
Perinatal endocrine panels are organized around functional axes, and common analytes include:
- Pregnancy maintenance markers: total hCG, free beta-hCG, progesterone, estradiol (E2), free estriol (uE3), and inhibin A.
- Thyroid panel: TSH, free T4, free T3, total T4 with pregnancy-adjusted reference ranges, thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb), and TSH receptor antibodies (TRAb) in Graves' disease follow-up.
- Glucose metabolism: fasting plasma glucose, 75-g OGTT at 0, 1, and 2 hours, HbA1c, insulin, and C-peptide for insulin resistance and beta-cell function assessment.
- Adrenal and androgen markers: cortisol, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate (DHEA-S), androstenedione, 11-deoxycortisol, aldosterone, and plasma renin activity where clinically indicated.
- Pituitary and placental hormones: prolactin, human placental lactogen, insulin-like growth factor 1 (IGF-1), and pregnancy-associated plasma protein A (PAPP-A) as part of first-trimester combined screening.
- Calcium and bone metabolism: 25-hydroxyvitamin D, intact parathyroid hormone (PTH), calcium (total and ionized), phosphorus, and magnesium.
- Neonatal screening analytes: TSH for congenital hypothyroidism and 17-hydroxyprogesterone for classic 21-hydroxylase deficiency, with second-tier steroid profiling where programs require it.
Testing Methods
Immunoassay platforms form the analytical backbone of perinatal endocrine testing. Chemiluminescent immunoassay (CLIA), electrochemiluminescent immunoassay (ECLIA), and chemiluminescent microparticle immunoassay formats provide automated, high-throughput quantification of peptide and steroid hormones with typical turnaround times of a few hours. Enzyme-linked immunosorbent assay (ELISA) remains in use for lower-volume antibody and specialty markers.
Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is increasingly applied to steroid hormone panels because it offers superior analytical specificity, simultaneous multi-analyte profiling, and minimal interference from cross-reacting compounds—an important consideration in pregnancy, when elevated sex hormone concentrations can bias immunoassay results. LC-MS/MS is the preferred confirmatory method for abnormal newborn screening results and for second-tier CAH steroid profiling.
Glucose is measured by hexokinase or glucose oxidase enzymatic methods on validated chemistry analyzers, while HbA1c is determined by boronate-affinity or ion-exchange HPLC, cation-exchange capillary electrophoresis, or certified enzymatic methods traceable to the IFCC reference system. Total testing quality is supported by ISO 15189 or ISO/IEC 17025 accreditation frameworks, participation in external quality assessment (proficiency testing) schemes, and verification of trimester-specific reference intervals in accordance with CLSI EP and C28 series documents.
Applications
Clinical applications of perinatal endocrine testing span the entire pregnancy and newborn timeline:
- Early pregnancy monitoring: serial quantitative hCG for viability assessment, ectopic pregnancy evaluation, and trophoblastic disease follow-up.
- Recurrent or threatened pregnancy loss workup: progesterone, prolactin, thyroid function, and thyroid autoantibodies to guide luteal support and endocrine correction.
- Gestational diabetes mellitus diagnosis and monitoring: universal 75-g OGTT at 24–28 weeks per WHO and IADPSG-aligned criteria, with HbA1c and fructosamine used selectively for glycemic tracking where erythrocyte turnover is normal.
- Maternal thyroid disease management: TSH and free T4 monitoring each trimester, TPOAb risk stratification for miscarriage and preterm birth, and TRAb measurement near delivery to evaluate neonatal hyperthyroidism risk.
- Newborn screening: population-based detection of congenital hypothyroidism via TSH and classic CAH via 17-hydroxyprogesterone, enabling hormone replacement within the first two weeks of life and prevention of irreversible neurodevelopmental or salt-wasting sequelae.
- Neonatal endocrine consultation: workup of neonatal hypoglycemia with insulin, C-peptide, ketones, and cortisol; ambiguous genitalia evaluation with comprehensive steroid panels by LC-MS/MS; and congenital hypothyroidism confirmation with serum TSH and free T4.
- Bone and mineral health: 25-hydroxyvitamin D and calcium-phosphate panels to manage maternal deficiency and reduce neonatal hypocalcemia risk.
FAQ
When during pregnancy should thyroid function be tested?
Testing is recommended at the first prenatal visit for women with a history of thyroid disease, autoimmune disease, infertility, miscarriage, or family history, and TSH with free T4 should be rechecked at least once per trimester in treated patients. Many clinical guidelines also support opportunistic or universal early-pregnancy TSH screening given the high prevalence of subclinical hypothyroidism and its association with adverse obstetric outcomes.
How is gestational diabetes testing performed?
The standard protocol is a one-step 75-g OGTT performed at 24–28 weeks of gestation after an overnight fast of 8–14 hours, with venous plasma glucose measured at 0, 1, and 2 hours. Diagnosis is made when any single value meets or exceeds the WHO/IADPSG thresholds of 5.1, 10.0, and 8.5 mmol/L respectively; high-risk women may be tested earlier using standard diabetes criteria.
Why is newborn TSH screening collected at 48–72 hours of age?
This window balances two physiological phenomena: the neonatal TSH surge that peaks at 30 minutes after birth and declines over the first 24–48 hours, and the need to detect congenital hypothyroidism before hospital discharge. Earlier collection increases false positives due to the surge, while delayed collection postpones life-critical treatment. Protein feeding of at least 24 hours is also required for valid 17-hydroxyprogesterone screening.
What does an elevated newborn 17-hydroxyprogesterone result mean?
An elevated 17-hydroxyprogesterone suggests possible classic 21-hydroxylase deficiency, the most common cause of congenital adrenal hyperplasia. However, results are influenced by prematurity, low birth weight, stress, and collection timing, so abnormal screens are confirmed with a second dried blood spot, serum steroid measurement by LC-MS/MS, and when necessary, CYP21A2 molecular testing before lifelong glucocorticoid therapy is initiated.
Why are pregnancy-specific reference intervals so important?
Estrogen-driven TBG elevation raises total T4, hCG cross-stimulates the TSH receptor in the first trimester suppressing TSH, cortisol-binding globulin increases cortisol, and placental steroids alter steroid immunoassay performance. Applying non-pregnant reference intervals can therefore generate both false-positive and false-negative interpretations, which is why laboratories must establish or verify trimester-specific intervals and annotate reports accordingly.
How should perinatal endocrine samples be stored and transported?
Serum for peptide hormones and thyroid testing is stable refrigerated at 2–8°C for 24–72 hours and should be frozen at -20°C or below for longer storage, while steroid hormones and vitamin D are generally stable refrigerated for several days. Glucose samples must be collected in fluoride-oxalate tubes and centrifuged promptly to prevent glycolytic loss, and dried blood spot cards require drying, low-humidity transport with desiccant, and avoidance of heat exposure to preserve analyte integrity.